Compare BLX & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLX | JANX |
|---|---|---|
| Founded | 1977 | 2017 |
| Country | Panama | United States |
| Employees | 322 | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | N/A | 2021 |
| Metric | BLX | JANX |
|---|---|---|
| Price | $43.11 | $13.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $60.27 |
| AVG Volume (30 Days) | 139.8K | ★ 2.3M |
| Earning Date | 10-28-2025 | 11-06-2025 |
| Dividend Yield | ★ 5.67% | N/A |
| EPS Growth | ★ 9.67 | N/A |
| EPS | ★ 6.00 | N/A |
| Revenue | ★ $308,426,000.00 | $10,000,000.00 |
| Revenue This Year | $18.35 | N/A |
| Revenue Next Year | $6.56 | N/A |
| P/E Ratio | $7.34 | ★ N/A |
| Revenue Growth | ★ 10.24 | N/A |
| 52 Week Low | $31.14 | $13.28 |
| 52 Week High | $48.38 | $61.59 |
| Indicator | BLX | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 36.68 | 26.48 |
| Support Level | $43.60 | $13.82 |
| Resistance Level | $44.73 | $14.49 |
| Average True Range (ATR) | 0.78 | 0.47 |
| MACD | -0.09 | 0.36 |
| Stochastic Oscillator | 2.56 | 4.69 |
Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.